CASE REPORT

Operable synchronous ampullary carcinoma and hepatocellular carcinoma: a case report and review of the literature

Marson Davidson1,*, Miriam Aioub2, Martin Gutierrez3, Kunchang Song4, Ellen Hagopian1, and Martin Karpeh1

1Department of Surgery, Hackensack University Medical Center, Hackensack, NJ 07601, USA, 2Rutgers New Jersey Medical School, Newark, NJ 07103, USA, 3Department Medical Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA, and 4Department of Pathology, Hackensack University Medical Center, Hackensack, NJ 07601, USA

*Correspondence address. Department of Surgery, Hackensack University Medical Center, 20 Prospect Avenue, Suite 406, Hackensack, NJ 07601, USA.
Tel: +1-55-19-96-8879; Fax: +1-55-19-96-0799; E-mail: Marson.Davidson@hackensackmeridian.org

Abstract

We report a rare case of synchronous double primary malignancies of the liver and ampulla. A 70-year-old white female was diagnosed with ampullary and hepatocellular carcinoma. The management and outcome of this rare case of synchronous double primary hepatic and periampullary malignancies, amenable to surgical resection is discussed.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide with an annual incidence of at least 6 per 100,000 in 2010. The number of deaths per year due to HCC is virtually identical to the worldwide incidence, delineating the lethality of this disease [1]. Ampullary adenocarcinomas are rare and account for 0.5% of gastrointestinal malignancies [2]. The etiology of ampullary cancers is unknown. Only one case of synchronous HCC and pancreatic cancer has been reported in the literature [3]. Furthermore, there are no reports of resected synchronous HCC and periampullary carcinomas. We herein report the first case of simultaneous resection of synchronous hepatocellular and ampullary carcinomas.

CASE REPORT

A 70-year-old woman presented with right-sided abdominal pain, nausea, vomiting and fever. She had a history of diabetes, hypertension and hypercholesterolemia. She smoked 0.5 pack/day and denied alcohol abuse. There was no significant family history. On admission her vital signs were within normal limits. On physical exam her sclera were anicteric. Her abdomen was soft, non-tender, non-distended with no palpable masses. Laboratory studies revealed: Alk Phos 126 IU/L, total bilirubin 2.0 mg/dL, AST 63 IU/L, ALT 58 IU/L, tumor markers showed AFP 226 ng/mL (normal 0.0–8), CA 19-9 959 unit/mL (normal 0–35) and carcinoembryonic antigen (CEA) 3.9 ng/mL (normal 0–3). Hepatitis C antibody was reactive and Hepatitis B core AB negative. CAT-scan of the abdomen revealed a 1.3 cm mass in the...
head of the pancreas with intrahepatic and extrahepatic ductal dilatation (Fig. 1a). MRI of the abdomen showed a 3.7 cm mass in segment VI of the liver (Fig. 1b). ERCP with bile duct brushings was performed and consistent with malignancy. EUS demonstrated a 2.6 cm mass in the head of the pancreas with portal vein involvement. Ultrasound guided biopsy of the liver was consistent with HCC. (Fig. 2). Routine staging CT scan of the chest showed a prominent 2.1 cm pre-tracheal lymph node. Endobronchial ultrasound guided-fine needle aspiration (FNA) of this lymph node showed no evidence of malignant cells.

Given the concern for portal vein involvement on EUS the pancreatic head lesion was deemed borderline resectable and a neoadjuvant approach was preferred. Prior to initiation of chemotheraphy a staging laparoscopy and liver biopsy was performed. At operation there was no evidence of peritoneal carcinomatosis, metastatic disease or gross liver cirrhosis. On final pathology the liver lesion stained positive for alphafetoprotein (AFP) and hepatocyte specific antigen (HSA) supporting the diagnosis of a primary hepatocellular carcinoma. The uninvolved liver had no evidence of cirrhosis. The patient received neoadjuvant FOLFIRINOX followed by re-imaging. Repeat CT scan showed no evidence of disease progression. Pancreaticoduodenectomy with synchronous liver resection was offered. A classic Whipple procedure was performed with a duct to mucosal pancreatico-jejunostomy. A parenchyma-sparing segment VI non-anatomic liver resection was then performed. She was discharged home on post-operative Day 6. Pathology revealed a 6 cm poorly differentiated hepatocellular carcinoma (Fig. 3) and a 1 cm intra-ampullary carcinoma extending into proximal stomach and distal bile duct.

**DISCUSSION**

Synchronous malignancies are defined as those that present simultaneously or within a 6-month period of each other. The diagnosis of synchronous malignancies of hepato-pancreatico-biliary origin is rare. Operable primary ampullary and liver cancer is even less common. Differentiating ampullary carcinoma from other periampullary malignancies may be clinically as well as pathologically difficult. Ampullary cancers are uncommon and account for 15–25% of cancers in the periampullary region. Overall, 5-year survival after resection of ampullary cancer is superior to that of pancreatic cancer (43.3 vs 7–27%, respectively) [4, 5]. Pancreatic head adenocarcinoma is however much more common and more likely to present with metastatic disease.

Hepatic lesions in the setting of a peripancreatic adenocarcinoma is metastatic until proven otherwise. While hepatocellular carcinoma is the most common primary cancer of the liver it is usually found in the setting of liver cirrhosis, chronic hepatitis B or C infection or non-alcoholic fatty liver disease. Even though our patient was infected with hepatitis C, her hepatocellular carcinoma developed in a non-cirrhotic liver. The incidence of
Operable synchronous ampullary carcinoma and hepatocellular carcinoma

Care should be taken to rule out metastatic disease in patients with synchronous malignancies particularly when one of the lesions is hepatic. In this case the possibility of synchronous intra and extrahepatic biliary tumors was not considered given the radiographic characteristics of the hepatic lesion. The MRI revealed a hyperintense lesion, heterogeneous enhancement with central washout and delayed capsular enhancement, consistent with primary hepatocellular carcinoma.

Preoperative biopsy of the hepatic lesion stained positive for AFP and HSA supporting the diagnosis of a primary hepatocellular carcinoma.

Synchronous ampullary and hepatocellular carcinoma has not been reported in the literature previously. There have been reports of synchronous unresectable pancreatic and hepatocellular carcinomas [3]. We believe this is the first report of synchronous resectable ampullary and hepatocellular carcinomas.

The patient has recovered well from surgery. She has completed adjuvant chemotherapy as well as sofosbuvir and daclatasvir for hepatitis C. At 1 year after diagnosis she is without evidence of recurrent disease.

CONFLICT OF INTEREST STATEMENT
None declared.

REFERENCES
1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
2. Albores-Saavedra J, Schwartz AM, Batch K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009;100:598–605.
3. Yadav Y, Dipanjan P, Yashwant F, Chhagan B. A rare case report: carcinoma pancreas with hepatocellular carcinoma. Indian J Palliat Care 2014;20:53–6.
4. Qiao Q, Zhao Y, Ye M. Carcinoma of the ampulla of vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007;31:137–43.
5. Garcea G, Dennison AR, Pattenden CJ. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008:999–132.
6. van Meer S, van Erpecum KJ, Sprengers D. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol 2016;28:352–9.
7. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D’Errico A, Simon N, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413–5.
8. Nash KL, Woodall T, Brown ASM, Davies SE, Graeme AJM. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010;16:4061–65.
9. Gaddikeri S, McNeely M, Wang C, Bhargava P, Dighe M, Yeh M, et al. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol 2014;203:34–47.
10. Feng X, Su Y, Zheng S, Xia F, Ma K, Li X, et al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB (Oxford) 2017;19:667–74.